Latest news with #HDFCMutualFund
Mint
7 days ago
- Business
- Mint
HDFC Mutual Fund raises stake in THIS Radhakishan Damani-owned stock to 5%. Details here
HDFC Mutual Fund, India's third-largest fund house by assets under management (AUM), raised its stake in logistics company Blue Dart to above 5%, according to a filing shared with the exchanges. The stock is also part of ace investor and DMart promoter Radhakishan Damani's portfolio. As of the June quarter shareholding pattern, Damani held a 1.19% stake in Blue Dart Express, valued at nearly ₹ 164 crore. Meanwhile, HDFC Mutual Fund saw its stake in the company climbing to 5.01% from 4.85% earlier as it acquired 38,934 shares of Blue Dart, representing a 0.16% stake. The stake was acquired via the open market. The mutual fund holds a stake in the logistics services provider via 12 schemes. The company recently announced its April-June quarter (Q1) results for the financial year 2025-26, wherein it reported a nearly 9% fall as higher expenses offset a rise in volumes. The company said its consolidated net profit fell 8.6% year-on-year (YoY) to ₹ 48.83 crore in the quarter ended June 30. Its revenue from operations, however, rose 7.4% YoY to ₹ 1442 crore, while expenses grew 8.3% YoY to ₹ 1,386 crore. Commenting on the company's performance, Balfour Manuel, Managing Director, Blue Dart Express, said, 'Blue Dart continues to build strong momentum, driven by substantial traction across both B2B and B2C products. Our focus on strategically identified high-growth areas is beginning to yield results, supported by timely investments in new hubs, automation, and digital capabilities.' 'In a landscape marked by evolving trade dynamics and tariff shifts, our commitment to reliability and time-definite services remains unwavering. To sustain this growth trajectory, we are making front-loaded investments that strengthen our operational backbone,' he added. Blue Dart Express shares traded 0.10% higher at ₹ 5813.40 despite a sharp selloff in the Indian stock market. The stock has declined 28% in the last one year and is down 17% year-to-date (YTD). Disclaimer: This story is for educational purposes only. The views and recommendations expressed are those of individual analysts or broking firms, not Mint. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary.
Mint
21-07-2025
- Business
- Mint
Balkrishna Industries share price edges higher as HDFC Mutual Fund raises stake to 7.16%
Shares of Balkrishna Industries rose nearly 1 percent in intraday trade on July 21, following news that HDFC Mutual Fund had increased its stake in the company to 7.16 percent, up from 5.02 percent earlier. The move was seen as a positive signal by investors, reflecting HDFC MF's reinforced confidence in the long-term potential of the tyre manufacturer. According to regulatory disclosures, HDFC Mutual Fund increased its holding by 2.14 percent, raising its total shareholding in the company to 1,38,34,445 equity shares from the previous 97,05,222 shares. The acquisition was completed via open market transactions and disclosed as of July 17, 2025. The purchase was made through various schemes managed by HDFC Mutual Fund and executed under HDFC Trustee Company Ltd, acting on behalf of its numerous mutual fund schemes. Among the participating schemes are the HDFC Mid Cap Opportunities Fund, HDFC Flexi Cap Fund, HDFC Balanced Advantage Fund, HDFC Large and Mid Cap Fund, and HDFC's sectoral and index-based funds, including the Nifty 50 benchmark fund. This diversified allocation across multiple schemes indicates a collective conviction among HDFC MF's fund managers about the strategic potential of Balkrishna Industries, particularly in its niche segment of off-highway tyres catering to agricultural, industrial, and construction equipment. The latest stake hike comes after HDFC MF's last reported holding on December 20, 2024, when its total ownership stood at 5.02 percent. At present, Balkrishna Industries has a paid-up capital of ₹ 38.66 crore, comprising 19.33 crore equity shares of ₹ 2 each. Following the announcement, shares of Balkrishna Industries climbed 0.8 percent to hit the day's high of ₹ 2,769.40. The stock, however, continues to trade nearly 18 percent below its 52-week high of ₹ 3,375.40, touched in August 2024. On the downside, the stock had marked its 52-week low of ₹ 2,157.20 in April 2025. Despite recent volatility, July has seen a sharp rebound, with the stock rallying 13 percent month-to-date, suggesting renewed investor interest possibly triggered by institutional accumulation. Over the last one year, the stock has declined 12.5 percent, reflecting broader sectoral pressures and cyclicality in the off-highway tyre market. Monthly performance has been mixed — down 1 percent in June, 7.5 percent in May, up 4.7 percent in April, down 2.3 percent in March, and deeper corrections of 5.6 percent in February and 5 percent in January. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
16-07-2025
- Business
- Economic Times
Vishal Mega Mart, Tech Mahindra among stocks that HDFC Mutual Fund bought and sold in June
HDFC MF rebalances June portfolio by increasing stake in 412 stocks and exiting 12, while adding new bets like Capital Infra Trust and Ellenbarrie Gases. HDFC Mutual Fund, the third largest fund house based on assets managed, increased its exposure in 412 stocks which includes Vishal Mega Mart, State Bank of India, and 410 stocks whereas it reduced its exposure in 170 stocks which includes Tech Mahindra, Infosys and other stocks. The other stocks where exposure was increased in June includes Hindalco Industries, ICICI Bank, Bank of Baroda, Ambuja Cements, Kaynes Technology India, Maruti Suzuki India, Dabur India, Hindustan Zinc, Mazagon Dock Shipbuilders, and Asian Paints. Also Read | HDFC Defence Fund picks up smallcap stock that surged 300% in 3 years Apart from Tech Mahindra and Infosys, the other stocks where the fund house reduced its exposure includes Coal India, ITC, Bajaj Finance, HCL Technologies, Axis Bank, RIL, IndusInd Bank, TCS, Eicher Motors, Swiggy, Wockhardt, HPCL, and Tata Motors. The fund house added three new stocks in its portfolio which were Capital Infra Trust, Ellenbarrie Industrial Gases, and Ventive Hospitality. Around 75 lakh shares of Capital Infra Trust and 7.25 lakh shares of Ellenbarrie Industrial Gases were added to the portfolio in June. Also, the fund house added 359 shares of Ventive Hospitality. The fund house made complete exit from 12 stocks which includes Swaraj Engines, Ujjiva Small Finance Bank, Tamilnad Mercantile Bank, Rajesh Exports, Mahindra Lifespace Developers, Sunteck Realty, FDC, Easy Trip Planners, Laxmi Organic Industries, and Prism were around 12 unique stocks in the portfolio of HDFC Mutual Fund which included Bajaj Healthcare, BEML Land Assets, OCCL, Ramco Systems, TV Today Network, Oriental Carbon & Chemicals, Popular Vehicles & Services, and Sadbhav Infrastructure industry wise shareholding pattern of the fund was 33.27% in financial services, 16.67% in consumer discretionary, 9.14% in industrials, 8.84% in healthcare, 7.51% in information technology, 5.98% in commodities, and 5.48% in energy. Also Read | Midcaps and Gold outperform: 10-year scorecard of key asset classes It also had 3.74% in FMCG, 3.66% in telecommunication, 3.41% in services, and lastly 2.29% in Mutual Fund had an AUM of Rs 8.71 lakh crore as on June 30, 2025 against an AUM of Rs 8.44 lakh crore in May witnessing a surge by Rs 27,295 crore.
Time of India
11-07-2025
- Business
- Time of India
Glenmark Pharmaceuticals shares rally up to 20%, mutual funds lead the charge over retail investors
The shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day's high of Rs 2,286 following a landmark $2 billion licensing deal with U.S. pharma giant AbbVie for its cancer drug, ISB 2001. While the announcement caught the attention of retail investors, the real winners were India's top mutual funds . pradee According to the data on BSE, mutual fund holdings in Glenmark Pharma rose from 9.11% in June 2023 to 14.60% by March 2025 (the last available data). Best MF to invest Looking for the best mutual funds to invest? Here are our recommendations. View Details » by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Live by the Beach at Sunteck's 2/3BHK Homes starts @₹98L+ Sunteck Realty Learn More Undo Also Read | Investors' pour Rs 47,000 crore in midcap & smallcap mutual funds in H1 CY25. What are they really chasing? Promoters hold around 46% and FIIs hold around 23.16% as on March 2025, according to the last available data on BSE. Public shareholding data shows that the retail investors' holding has declined from 9.99% in June 2023 to 7.69% in March 2025 (individual shareholders holding nominal share capital up to Rs 2 lakh) Live Events According to the last available data, Prashant Jain's 3P India Equity Fund held nearly 1.02% in Glenmark, while Ashish Dhawan held 1.77% in this stock. Mutual funds holding Mutual funds had around 4.16 crore shares of Glenmark Pharmaceuticals in May worth Rs 6,072 crore. Around 27 mutual fund houses had this stock in their portfolio as on May 31, 2025. Out of 27 AMCs, HDFC Mutual Fund and Mirae Asset Mutual Fund had the highest number of shares in their respective portfolios. HDFC Mutual Fund had around 1.27 crore shares of Glenmark Pharmaceuticals worth Rs 1,863 crore in May followed by Mirae Asset Mutual Fund which had 1.01 crore shares of this stock worth Rs 1,473 crore. Around 13 funds from HDFC Mutual Fund had this stock in their portfolio, of which HDFC Mid Cap Fund had the highest number of shares of around 87.78 lakh worth Rs 1,279 crore, followed by HDFC Manufacturing Fund which had 12 lakh shares of this stock worth Rs 174 crore. Around 17 funds from Mirae Asset Mutual Fund had exposure in this stock with Mirae Asset Large & Midcap Fund having the highest number of shares of 33.13 lakh worth Rs 482 crore. Mirae Asset Nifty Total Market Index Fund had the lowest number of shares of 319 in its portfolio. Also Read | How much money did ICICI Prudential's star fund manager Sankaran Naren make in FY25? Kotak Mutual Fund had 19.66 lakh shares of Glenmark Pharmaceuticals in its portfolio worth Rs 286 crore. Eight funds from the fund house had this stock in their portfolio and Kotak Arbitrage Fund had the highest number of shares of 13.48 lakh. SBI Mutual Fund , the largest mutual fund house based on assets managed, had 4.98 lakh shares of this stock worth Rs 72 crore, followed by Motilal Oswal Mutual Fund which had 2.49 lakh shares worth Rs 36.29 crore. PPFAS Mutual Fund had 3,575 shares in its portfolio worth Rs 0.52 crore. Angel One Mutual Fund and Unifi Mutual Fund which are new entrants in the mutual fund industry had around 453 and 325 shares of this stock in their respective portfolios. FII's holding According to the last available data, FII's holding showed a mixed trend. Smallcap World Fund, INC had 3.21% holding in this stock compared to 4.52% in June 2023. Government Pension Fund Global had 3.25% holding in March 2025 compared to 2.26% in June 2023. Ellipsis Partners LLC had 1.11% exposure in this stock compared to 1.68% in June 2023. Glenmark Pharmaceuticals step-down wholly owned subsidiary, Ichnos Glenmark Innovation (IGI), signed an exclusive global licensing agreement with US-based AbbVie for its experimental cancer drug, ISB 2001. ISB 2001, currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma, will be jointly developed under the deal. AbbVie will hold exclusive rights to develop, manufacture, and commercialise the drug in North America, Europe, Japan, and China. Meanwhile, Glenmark will retain rights for Emerging Markets, including Asia (excluding Japan and China), Latin America, Russia/CIS, the Middle East, Africa, Australia, New Zealand, and South Korea. Under the agreement, IGI Therapeutics SA—a subsidiary of Ichnos Glenmark Innovation—will receive a $700 million upfront payment and is eligible for up to $1.225 billion in milestone payments, along with tiered, double-digit royalties on net sales.
Economic Times
11-07-2025
- Business
- Economic Times
Glenmark Pharmaceuticals shares rally up to 20%, mutual funds lead the charge over retail investors
The shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day's high of Rs 2,286 following a landmark $2 billion licensing deal with U.S. pharma giant AbbVie for its cancer drug, ISB 2001. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mutual funds holding Tired of too many ads? Remove Ads FII's holding The shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day's high of Rs 2,286 following a landmark $2 billion licensing deal with U.S. pharma giant AbbVie for its cancer drug, ISB the announcement caught the attention of retail investors, the real winners were India's top mutual funds . pradeeAccording to the data on BSE, mutual fund holdings in Glenmark Pharma rose from 9.11% in June 2023 to 14.60% by March 2025 (the last available data).Also Read | Investors' pour Rs 47,000 crore in midcap & smallcap mutual funds in H1 CY25. What are they really chasing? Promoters hold around 46% and FIIs hold around 23.16% as on March 2025, according to the last available data on BSE. Public shareholding data shows that the retail investors' holding has declined from 9.99% in June 2023 to 7.69% in March 2025 (individual shareholders holding nominal share capital up to Rs 2 lakh)According to the last available data, Prashant Jain's 3P India Equity Fund held nearly 1.02% in Glenmark, while Ashish Dhawan held 1.77% in this funds had around 4.16 crore shares of Glenmark Pharmaceuticals in May worth Rs 6,072 crore. Around 27 mutual fund houses had this stock in their portfolio as on May 31, of 27 AMCs, HDFC Mutual Fund and Mirae Asset Mutual Fund had the highest number of shares in their respective portfolios. HDFC Mutual Fund had around 1.27 crore shares of Glenmark Pharmaceuticals worth Rs 1,863 crore in May followed by Mirae Asset Mutual Fund which had 1.01 crore shares of this stock worth Rs 1,473 13 funds from HDFC Mutual Fund had this stock in their portfolio, of which HDFC Mid Cap Fund had the highest number of shares of around 87.78 lakh worth Rs 1,279 crore, followed by HDFC Manufacturing Fund which had 12 lakh shares of this stock worth Rs 174 17 funds from Mirae Asset Mutual Fund had exposure in this stock with Mirae Asset Large & Midcap Fund having the highest number of shares of 33.13 lakh worth Rs 482 crore. Mirae Asset Nifty Total Market Index Fund had the lowest number of shares of 319 in its Read | How much money did ICICI Prudential's star fund manager Sankaran Naren make in FY25? Kotak Mutual Fund had 19.66 lakh shares of Glenmark Pharmaceuticals in its portfolio worth Rs 286 crore. Eight funds from the fund house had this stock in their portfolio and Kotak Arbitrage Fund had the highest number of shares of 13.48 lakh. SBI Mutual Fund , the largest mutual fund house based on assets managed, had 4.98 lakh shares of this stock worth Rs 72 crore, followed by Motilal Oswal Mutual Fund which had 2.49 lakh shares worth Rs 36.29 Mutual Fund had 3,575 shares in its portfolio worth Rs 0.52 crore. Angel One Mutual Fund and Unifi Mutual Fund which are new entrants in the mutual fund industry had around 453 and 325 shares of this stock in their respective to the last available data, FII's holding showed a mixed trend. Smallcap World Fund, INC had 3.21% holding in this stock compared to 4.52% in June 2023. Government Pension Fund Global had 3.25% holding in March 2025 compared to 2.26% in June 2023. Ellipsis Partners LLC had 1.11% exposure in this stock compared to 1.68% in June Pharmaceuticals step-down wholly owned subsidiary, Ichnos Glenmark Innovation (IGI), signed an exclusive global licensing agreement with US-based AbbVie for its experimental cancer drug, ISB 2001, currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma, will be jointly developed under the deal. AbbVie will hold exclusive rights to develop, manufacture, and commercialise the drug in North America, Europe, Japan, and China. Meanwhile, Glenmark will retain rights for Emerging Markets, including Asia (excluding Japan and China), Latin America, Russia/CIS, the Middle East, Africa, Australia, New Zealand, and South the agreement, IGI Therapeutics SA—a subsidiary of Ichnos Glenmark Innovation—will receive a $700 million upfront payment and is eligible for up to $1.225 billion in milestone payments, along with tiered, double-digit royalties on net sales.
